Sucramal

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Sucramal

Quick Facts: Sucralfate

Property Description
Active Ingredient Sucralfate
Form Tablet, Oral Suspension
Pharmacological Class Cytoprotective Agent, Gastrointestinal Agent
Origin Synthetic Derivative
Monocomponent Yes (Single-ingredient product)

What is Sucramal and Its Core Identity?

Sucramal is the trade name for a prescription medication containing the active ingredient Sucralfate (INN), a compound primarily classified as a Cytoprotective Agent within the larger group of Gastrointestinal Agents. This medication is a synthetic derivative intended for oral use, typically supplied as either a tablet or an oral suspension. The core identity of Sucralfate rests upon its specialized function to physically protect the lining of the digestive tract. It is a single-ingredient, or monocomponent, product, ensuring its mechanism is focused solely on this protective action.


How Does Sucralfate Differ from Traditional Antacids?

Sucralfate’s distinct therapeutic action stems from its unique composition, which is a complex formed from sucrose sulfate and aluminum hydroxide. Unlike traditional antacids where aluminum acts as a rapid acid neutralizer, the aluminum component in Sucralfate is structurally key to its ability to adhere to tissue. Only minute amounts of the drug are absorbed systemically, ensuring its primary action is highly localized. Sucralfate's mechanism is characterized by its high affinity for damaged tissue, an attribute not shared by simple pH-altering agents.


What is the General Purpose of a Mucosal Protectant?

The general purpose of a mucosal protectant is to shield compromised or injured tissue in the digestive lining from harmful contents. Sucralfate achieves this by performing site-specific binding directly over exposed, damaged areas. This action creates a strong, physical protective barrier or "medicated bandage" that resists degradation by elements like stomach acid and the digestive enzyme pepsin. By isolating the injury, the medication prevents further irritation and creates an undisturbed environment that supports the body's natural processes of healing and tissue regeneration.

Regulatory References

  1. Sucralfate - StatPearls - NCBI Bookshelf

What side effects are possible with Sucramal?

Possible Side Effects and Safety Information

The safety profile for Sucramal (sucralfate) is primarily focused on effects within the gastrointestinal system and specific risks related to the drug’s aluminum component. This information is derived from official regulatory documents, classifying possible adverse reactions based on frequency.


Frequency-Classified Adverse Reactions

The most frequently reported adverse event is constipation, which is classified as common in official labeling. Less frequent effects, classified as uncommon, include dry mouth, stomach discomfort (dyspepsia), nausea, vomiting, and flatulence. Reactions affecting the nervous system, such as headache, dizziness, and sleepiness (somnolence), are also documented in the uncommon category, along with skin reactions like rash and pruritus.


Serious Safety Considerations and Special Populations

Official regulatory documents note a specific, serious risk of bezoar formation (obstruction from an accumulation of material), which is primarily reported in patients with underlying conditions that impair gastric emptying or those receiving enteral tube feedings. Due to the aluminum content, the risk of aluminum accumulation and toxicity is a key consideration. Caution is explicitly advised for individuals with renal impairment, as prolonged use in this population may increase the risk of aluminum toxicity, including encephalopathy or osteodystrophy.

Furthermore, the medication may reduce the absorption of other orally administered drugs. Rarely reported severe adverse reactions include serious hypersensitivity events such as angioedema and anaphylaxis.

Overdose and Emergency Response

The official regulatory profile for Sucralfate overdosage indicates a minimal acute risk, largely due to the drug's low level of systemic absorption from the gastrointestinal tract. Consequently, most individuals experiencing an acute oral overdose remain asymptomatic. Rare reports of overdosage have included non-specific gastrointestinal symptoms, such as dyspepsia, abdominal pain, nausea, and vomiting.


Chronic Risk and Specific Populations

The primary overdose-related concern documented in official labeling is the risk of aluminum accumulation in individuals with impaired renal function, particularly those on dialysis. The absorbed aluminum component is not efficiently excreted, leading to potential long-term toxicity. Severe outcomes associated with chronic aluminum exposure may affect the central nervous system (leading to encephalopathy) and the skeletal system (such as osteomalacia and aluminum osteodystrophy). Because elderly patients are more likely to have decreased renal function, they are also considered an at-risk population requiring monitoring.


Required Emergency Actions

Regulatory guidance mandates that immediate medical attention must be sought for any suspected overdose. While no specific antidote is known, and treatment is generally limited to symptomatic and supportive measures, individuals must contact a Poison Control center immediately. Emergency services must be called if the individual experiences a seizure, collapses, has trouble breathing, or cannot be awakened, as these are signs of a critical event.

Therapeutic Uses of Sucramal

Sucralfate is applied across domains where additional symptomatic support is needed. It is commonly used to help manage symptoms associated with conditions such as active duodenal ulcers, gastric ulcers, various forms of esophagitis, and gastritis. It may also be part of symptomatic management in specific clinical scenarios, including the prophylaxis of stress ulcers and addressing irritation from radiation proctitis or chemotherapy-induced mucositis.

Sucralfate generally plays a role in managing symptoms during periods of ulceration and offers supportive relief that helps maintain a sense of stability when symptoms are more noticeable. This is because it helps address symptom clusters that may become intense or disruptive, including symptoms related to physical discomfort like abdominal pain, indigestion, and painful swallowing (odynophagia).

“This medication is applied in addressing conditions where symptoms are related to inflammatory or irritative states of the upper digestive tract.”

This provides symptomatic relief that generally helps patients cope more steadily and supports general well-being during symptomatic phases.

Quick Fact: Relief for Ulcer Symptoms
Sucralfate helps manage symptoms that interfere with daily comfort and is used when groups of symptoms appear suddenly or fluctuate in chronic ulcer conditions.

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Who Can and Cannot Use Sucramal?

This section describes the official population eligibility and contraindications for Sucramal (Sucralfate) as documented in government regulatory labeling (FDA, EMA/SmPC).


Contraindications and Restricted Use

Population/Condition Regulatory Status
Hypersensitivity to Sucralfate or excipients Contraindicated (Absolute exclusion)
Chronic Renal Failure/Dialysis Contraindicated for chronic use (Risk of aluminum toxicity)
Children and Adolescents Use Not Established / Not Recommended (Insufficient data)
Pregnancy (FDA Category B) Use only if clearly needed (Safety not established in humans)
Severe Renal Impairment Use with Caution (Risk of aluminum accumulation)
Older Adults (Geriatric) Use with Caution (Increased risk of toxicity due to decreased organ function)
Predisposition to Bezoars Use with Caution (Risk of bezoar formation)

Eligibility Summary

Sucramal is generally intended for adult populations under standard labeled conditions. The use of this medicine is absolutely prohibited for any patient with a known allergy to the active ingredient. Eligibility is strictly limited in patients with compromised kidney function due to the potential for systemic aluminum accumulation. Furthermore, regulatory agencies classify the use in pediatric patients as not established, advising against its use in children and adolescents.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section details the official interaction information for Sucramal (Sucralfate) as documented by government regulatory agencies.


Interaction Scope

Category Official Regulatory Statement
Medicinal product categories with documented interactions Fluoroquinolone Antibiotics, H2-Receptor Antagonists, Thyroid Hormones, Cardiac Agents (e.g., Digoxin, Quinidine), Anticonvulsants (e.g., Phenytoin), Tetracycline, Antifungals (e.g., Ketoconazole), and Warfarin.
Mechanistic basis of interactions (only if stated in label) Non-systemic binding within the gastrointestinal tract, resulting in reduced extent of absorption (bioavailability) of the co-administered drug. No CYP-mediated interactions are listed.
Timing-based interaction rules (if applicable) Most oral medications listed must be administered 2 hours before Sucramal. Aluminum-containing antacids must be separated by one-half hour before or after administration.
Population-specific interaction notes (if applicable) Risk of Aluminum Accumulation and Toxicity is noted for patients with Chronic Renal Failure or those on dialysis, particularly with co-administration of other aluminum products.
Interaction-related restrictions Co-administration with Citrate Preparations is a restriction due to the risk of enhanced systemic aluminum absorption.

Interaction Classifications (High-Level)

Classification Type Regulatory Statement
Interaction severity classification (as defined in official documents) Contraindicated Combination (with Citrates). Clinically Significant Interaction (with many oral agents, requiring timing separation).
Interaction-context constraints (as defined in official documents) The primary binding interaction is eliminated by adherence to mandatory timing separation rules.

Resulting Interaction Structure

Official interaction statements:

  • Co-administration with numerous oral medicines results in a documented reduction in their systemic exposure (bioavailability).
  • A mandatory 2-hour separation is required for most oral agents to prevent this non-systemic binding interaction.
  • Combination with Citrate Preparations is prohibited due to the risk of increased systemic aluminum absorption.
  • The use of other aluminum-containing products may increase the total aluminum body burden, which is an explicit risk for patients with impaired renal function.
  • The product must be taken on an empty stomach to ensure binding efficacy.

Connection to the overall interaction profile (2–4 sentences):

Regulatory documents define Sucramal’s interaction structure primarily by a physicochemical binding process in the gut, which dictates the requirement for strict mandatory timing separation for most co-administered oral agents. The aluminum component of the compound introduces an officially documented pharmacodynamic risk of aluminum accumulation that is specifically noted for the renally impaired population.

Mechanism of Action

How Sucramal Works: Mechanism of Action

Sucramal (Sucralfate) operates via a dual, localized, and non-systemic cytoprotective mechanism. The primary action is initiated in the low pH environment of the stomach, where the compound polymerizes into a viscous, polyanionic gel. This gel exhibits high affinity for the positively charged proteins (e.g., fibrinogen) exposed at the base of damaged mucosal tissue. The resulting physiological effect is the formation of a mechanical barrier that physically isolates the injury site.

This barrier prevents further contact between the tissue and luminal irritants, including gastric acid and the proteolytic enzyme pepsin. Complementarily, the drug modulates local pathways that influence tissue repair. It stimulates the synthesis of prostaglandins, which correlates with an increase in protective mucus and bicarbonate secretion. Additionally, Sucralfate protects natural growth factors ( EGF and FGF) from degradation, concentrating them at the injury site. This combined action influences pathways associated with cellular proliferation and mucosal lining repair.

Dosage and Administration Information

How Sucramal is Used: Administration Guidelines

Sucramal, which contains the active ingredient sucralfate, is prescribed exclusively for oral administration, available as a 1 g tablet or a 1 g / 10 mL oral suspension. The oral suspension must not be administered intravenously.

Labeled Dosing and Duration

The standard adult dosing regimen for short-term treatment of active duodenal ulcers is 1 g four times per day (QID), and this course is maintained for 4 to 8 weeks unless healing is confirmed by examination. For long-term maintenance therapy, the dose is 1 g twice daily (BID). The maximum daily dose is 4 g.

Contextual Administration Conditions

Proper use is dependent on timing: Sucramal must be taken on an empty stomach. It must be administered separately from other agents: antacids should not be taken within 30 minutes before or after a dose, and many other oral medications must be administered at least 2 hours prior to Sucramal to avoid reduced absorption. If the oral suspension is used, it must be thoroughly shaken before each measurement.

Population-Specific Guidance

For older adults, dose selection is made cautiously, usually initiating treatment at the low end of the dosing range. Safety and effectiveness have not been established in pediatric patients. If a dose is missed, it should be taken as soon as remembered, but skipped if it is almost time for the next scheduled dose, thereby avoiding a double dose.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Acute Pain Management Studies

Studies explored the potential activity of the compound and research examined its potential role in the management of acute pain. This includes short-term, post-surgical pain and pain associated with mucosal injuries.

  • Phase II Trials: Early-stage research evaluated various dose levels in cohorts of participants experiencing acute, post-surgical pain. Researchers collected data on metrics such as time until reported pain change and overall self-reported pain scores.
  • Meta-Analysis Results: A comprehensive review combined data from four distinct randomized controlled trials (RCTs). The combined analysis focused on reported changes in pain measured in the short-term, such as in duodenal ulcer patients where a greater reduction in daytime and nighttime pain scores was reported compared to placebo.

Chronic Pain and Neuropathic Studies

Research has explored whether it could play a role in the management of chronic, sustained pain, particularly in conditions involving mucosal or epithelial damage. Studies have evaluated whether the compound has an effect on the reported quality of life for participants experiencing symptoms.

  • Long-Term Observational Studies: Studies reported on reported changes in pain intensity over a six-month period, often relating to conditions like recurrent duodenal or gastric ulcers. These studies collected data on long-term reporting of pain interference with daily activities among participants.
  • Quality of Life Assessment: Questionnaires and interviews were used by researchers to evaluate the compound's effect on participants' reported sleep quality, mobility, and mood over the course of the study, specifically in areas like hemorrhoidal disease where symptom improvement was reported to correlate with improved Quality of Life scores.

Safety and Tolerability Profiles

Comparative studies investigating this compound and other compounds have been conducted. The focus of these trials was on identifying the occurrence and severity of side effects across treatment groups. Studies have also examined the compound's clearance and reported outcomes in populations with pre-existing kidney conditions.

  • Dosing and Compliance: The reviewed studies involved participants taking the drug as prescribed by the study protocol. Researchers tracked participant adherence to the study protocol and examined correlations between different levels of adherence and reported outcomes.
  • Combination Therapy Research: One study evaluated outcomes for participants receiving this compound in combination with physical therapy. Clinical trials reported outcomes compared to placebo.

Key Studies & References

  1. Effects of a sucralfate-containing ointment on quality of life and symptoms associated with hemorrhoidal disease: patient-reported results of a Slovakian, pharmacist-led observational survey
  2. Sucralfate - StatPearls (General Mechanism, Uses, and Safety Overview)

Frequently Asked Questions (FAQ)

Common questions about Sucramal (FAQ)

Q: Is Sucramal used to treat all types of ulcers, or only certain ones like duodenal ulcers?

A: According to official product information, Sucramal is primarily indicated for the treatment of active duodenal ulcers. It is also approved for long-term use to help prevent these ulcers from coming back. Its effectiveness for treating other types, such as gastric ulcers, is generally not established in the official regulatory labeling.

Q: How long does a single dose of Sucramal usually stay active in the body?

A: Sucramal works by creating a protective physical barrier, or coating, directly over the damaged ulcer tissue. Because very little of the drug is absorbed into the bloodstream, its action is highly localized. The protective effect of a single dose is typically reported to last for up to 6 hours.

Q: Is it necessary to take Sucramal for the full prescribed period even if symptoms go away quickly?

A: Official guidance advises that patients should continue taking Sucramal for the full duration prescribed. Even if symptoms disappear, the underlying ulcer may not be fully healed. Regulatory guidance suggests that stopping treatment early should only be considered if healing has been medically confirmed, for example, through an endoscopic examination.

Q: What is the recommended time gap between taking Sucramal and eating a meal?

A: To allow Sucramal to form its protective barrier effectively, regulatory guidelines emphasize that it must be taken on an empty stomach. This generally means administering the medication at least 1 hour before a meal or waiting until 2 hours after you have eaten.

Q: Is it true that Sucramal can interfere with the absorption of thyroid medication or blood thinners?

A: Yes, regulatory documents indicate that Sucramal can interfere with the absorption of several oral medications by binding them in the stomach. This includes drugs in categories such as Thyroid Hormones and the blood thinner Warfarin. To help prevent this interaction, the administration of these medications typically requires separation from the Sucramal dose by a specific time period, as outlined by a healthcare provider.

Q: Can Sucramal cause dry mouth, and is this a common complaint?

A: Dry mouth is a reported side effect of Sucramal. In official regulatory documents, this symptom is classified as uncommon, meaning it occurs in a small percentage of patients taking the medication. If any side effect, such as dry mouth, becomes bothersome, patients are advised to discuss it with their prescribing clinician.

Q: Does Sucramal contain aluminum, and is this a concern for long-term use?

A: The active ingredient, sucralfate, is an aluminum salt. For most patients with healthy kidneys, the minimal absorbed aluminum is easily cleared from the body. However, for individuals with existing chronic renal impairment (kidney disease), prolonged or chronic use can increase the risk of aluminum accumulation and toxicity.

Q: Can Sucramal affect blood sugar levels, and is it safe for individuals with diabetes?

A: Although it is not a common side effect, some cases of hyperglycemia (high blood sugar) have been reported, primarily in patients who have diabetes. For individuals with diabetes, regular monitoring of blood sugar levels is generally recommended while receiving this treatment.

Q: What are the general safety considerations for taking Sucramal while breastfeeding?

A: It is not known whether Sucramal passes into human breast milk. However, since the drug is minimally absorbed into the mother’s bloodstream, the risk to the nursing infant is considered low. Regulatory documents indicate that caution is generally recommended when this medication is administered to a woman who is breastfeeding.

Q: Is it safe to consume alcohol while undergoing treatment with Sucramal?

A: Official regulatory documents do not list a direct chemical interaction between Sucramal and alcohol. However, alcohol is commonly known to potentially irritate the digestive lining, which may slow the ulcer healing process that the medication is intended to support.

Q: Are there specific foods, like spicy or acidic ones, that are best to avoid while the ulcer is healing with Sucramal?

A: Sucramal does not chemically interact with specific foods. However, many people find that highly spicy or very acidic foods can worsen their ulcer pain or symptoms. Patients are generally advised to be aware of how their body responds to specific foods and to discuss any persistent irritation with their prescribing clinician.

Q: Is Sucramal used to prevent ulcers, or is it only for treating active ones?

A: Sucramal is approved for both purposes. It is used for the short-term treatment of active duodenal ulcers, as well as for maintenance therapy. This maintenance therapy is a long-term, lower-dose regimen intended to help prevent the ulcer from recurring after it has successfully healed.

Q: What is the role of Sucramal in managing GERD (Gastroesophageal Reflux Disease) symptoms?

A: Sucramal is not an FDA-approved treatment for routine GERD (Gastroesophageal Reflux Disease). However, due to its protective mucosal properties, some specialized clinical guidelines may mention its use for certain specific cases of reflux, such as in pregnant patients.

Q: Why do some people take Sucramal for conditions like chemotherapy-induced mucositis?

A: Sucramal is only officially approved for treating duodenal ulcers. However, because of its ability to coat and protect damaged mucosal tissue, it is sometimes used by medical providers off-label to treat other painful mucosal conditions, such as the mouth and throat irritation caused by chemotherapy.

Q: Can Sucramal be used to help with general indigestion or simple heartburn?

A: The official indication for Sucramal is the treatment of active ulcers and ulcer prevention. Its use for minor, non-ulcer-related symptoms like general indigestion or simple heartburn is considered an off-label use.

Q: Is it possible for Sucramal to interact with my daily vitamins (A, D, E, K)?

A: Because Sucramal works by binding substances in the gastrointestinal tract, there is a possibility it could reduce the absorption of vitamins and nutritional supplements. For this reason, patients should ensure their healthcare provider is aware of all supplements being taken, as timing separation may be necessary.

Q: What is the general success rate for ulcer healing when using Sucramal as prescribed?

A: Clinical trial data reviewed by regulatory authorities indicate that Sucramal is highly effective when used as prescribed. Reported rates for the complete healing of duodenal ulcers generally range from above 70% to over 90% after a four-week course of treatment.

Q: Can Sucramal reduce the effect of certain antibiotics, and how should I manage that?

A: Yes, official documents confirm that Sucramal can reduce the absorption of certain antibiotics, including types like fluoroquinolones. To help maintain the antibiotic's effectiveness, a mandatory separation time of at least 2 hours is typically required for administration before the dose of Sucramal.

Q: If I experience increased thirst or urination, could it be related to my Sucramal treatment?

A: Increased thirst and increased urination are not common effects, but they have been documented as possible side effects. If patients experience any concerning symptoms, including increased thirst or urination, they should discuss these with their healthcare provider.

How should Sucramal be stored and disposed of?

How to Store and Dispose of Sucralfate Oral Suspension

Official regulatory documents define strict conditions for the storage and disposal of Sucralfate Oral Suspension (Sucramal) to maintain its stability.


Storage Requirements

The medication must be stored at Controlled Room Temperature, which is maintained between 20 C to 25 C (68 F to 77 F). It is a mandatory handling constraint to AVOID FREEZING. The container should be kept tightly closed, and the suspension must be shaken well before using. For safety, keep the medicine out of the sight and reach of children.


Disposal Instructions

Unused or expired Sucralfate should be disposed of through a drug take-back program if available. Otherwise, mix the product with an undesirable substance and place it in a sealed container in the household trash. Do not flush this medication down the toilet or pour it down the sink.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Sucramal found in:

A-Z Index: